Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00512993
Status:
COMPLETED
Last Update Posted:
2015-03-05
First Post:
2007-08-03
Brief Title:
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
Sponsor:
German Breast Group
Organization:
German Breast Group
Study Overview
Official Title:
A Randomized Multicenter Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NATAN
Brief Summary:
The purpose of this study is to determine the event-free survival EFS after zoledronic acid for 5 years versus no postoperative treatment in patients with chemo-insensitive breast cancer ypT1-4 andor ypN1-3 after preoperative anthracyclinetaxane containing chemotherapy
Detailed Description:
The study is restricted to patients having had primary systemic chemotherapy for stage II and III breast cancer Participation in a preoperative chemotherapy trial investigating anthracycline and taxane based regimen is allowed but not mandatory for all patients Patients must have significant remaining tumor tissue in the breast andor axillary lymph node This implies resistance to further chemotherapy and a clinically relevant risk for relapse Bisphosphonates have a distinct mechanism of action and have demonstrated efficacy in the treatment of breast cancer with metastasis to the bone as well as adjuvant treatment after surgery of primary breast cancer The 3rd generation bisphosphonate zoledronic acid has a favorable toxicity profile and can be conveniently given to patients over a long term period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ABCSG 29 | None | None | None |
| NATAN | None | None | None |